Difference between revisions of "Camrelizumab (AiRuiKa)"
Warner-admin (talk | contribs) |
|||
(10 intermediate revisions by 2 users not shown) | |||
Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Esophageal squamous cell carcinoma]] | *[[Esophageal squamous cell carcinoma]] | ||
+ | *[[Hepatocellular carcinoma]] | ||
+ | *[[Classical Hodgkin lymphoma]] | ||
*[[Nasopharyngeal carcinoma]] | *[[Nasopharyngeal carcinoma]] | ||
+ | *[[Non-small cell lung cancer, squamous]] | ||
+ | *[[Non-small cell lung cancer, nonsquamous]] | ||
+ | |||
+ | ==History of changes in NMPA indication== | ||
+ | *2019-05-29: Initial approval | ||
+ | *2021-06-17: Approved combined with gemcitabine and cisplatin (GP) as a first-line treatment for the patients with recurrent or metastatic [[Nasopharyngeal_carcinoma|nasopharyngeal carcinoma (NPC)]]. ''(Based on CAPTAIN-1st)'' | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' HR-301210, SHR-1210 | *'''Code names:''' HR-301210, SHR-1210 | ||
− | *'''Brand | + | *'''Generic name:''' carrelizumab |
+ | *'''Brand names:''' AiRuiKa, Erica | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Line 17: | Line 26: | ||
[[Category:Anti-PD-1 antibodies]] | [[Category:Anti-PD-1 antibodies]] | ||
− | [[Category:Esophageal | + | [[Category:Esophageal squamous cell carcinoma medications]] |
+ | [[Category:Hepatocellular carcinoma medications]] | ||
+ | [[Category:Classical Hodgkin lymphoma medications]] | ||
[[Category:Nasopharyngeal carcinoma medications]] | [[Category:Nasopharyngeal carcinoma medications]] | ||
+ | [[Category:Non-small cell lung cancer, nonsquamous medications]] | ||
+ | [[Category:Non-small cell lung cancer, squamous medications]] | ||
− | [[Category: | + | [[Category:NMPA approved in 2019]] |
Latest revision as of 13:52, 22 January 2024
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, camrelizumab binds to and blocks the binding of PD-1, expressed on activated T lymphocytes, B cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens.
Toxicity management
Diseases for which it is used
- Esophageal squamous cell carcinoma
- Hepatocellular carcinoma
- Classical Hodgkin lymphoma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer, squamous
- Non-small cell lung cancer, nonsquamous
History of changes in NMPA indication
- 2019-05-29: Initial approval
- 2021-06-17: Approved combined with gemcitabine and cisplatin (GP) as a first-line treatment for the patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). (Based on CAPTAIN-1st)
Also known as
- Code names: HR-301210, SHR-1210
- Generic name: carrelizumab
- Brand names: AiRuiKa, Erica
- Drugs
- Intravenous medications
- Anti-PD-1 antibodies
- Esophageal squamous cell carcinoma medications
- Hepatocellular carcinoma medications
- Classical Hodgkin lymphoma medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer, nonsquamous medications
- Non-small cell lung cancer, squamous medications
- NMPA approved in 2019